Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-05-31
2010-06-22
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S140100, C424S145100, C424S158100, C424S085100, C514S002600, C514S008100, C530S351000, C530S387900, C530S388240, C530S388250
Reexamination Certificate
active
07740849
ABSTRACT:
Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sFlt-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5238819 (1993-08-01), Roberts et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5543138 (1996-08-01), Keith
patent: 5641636 (1997-06-01), Strauss et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5830847 (1998-11-01), Letarte et al.
patent: 5830879 (1998-11-01), Isner
patent: 5910482 (1999-06-01), Yallampalli et al.
patent: 5928641 (1999-07-01), Seon
patent: 5958715 (1999-09-01), Muller
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6258787 (2001-07-01), Isner
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6376199 (2002-04-01), Caniggia et al.
patent: 6399585 (2002-06-01), Larson et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6447768 (2002-09-01), Van Zonneveld et al.
patent: 6562957 (2003-05-01), Letarte et al.
patent: 6660534 (2003-12-01), McVicker et al.
patent: 6677300 (2004-01-01), Schreiner et al.
patent: 7030083 (2006-04-01), Schreiner et al.
patent: 7335362 (2008-02-01), Karumanchi et al.
patent: 7407659 (2008-08-01), Karumanchi et al.
patent: 7435419 (2008-10-01), Karumanchi et al.
patent: 2003/0049823 (2003-03-01), Sessa
patent: 2003/0099651 (2003-05-01), Leibovitz
patent: 2003/0114407 (2003-06-01), Monia et al.
patent: 2003/0114412 (2003-06-01), Ward et al.
patent: 2003/0144298 (2003-07-01), Curwen et al.
patent: 2003/0220262 (2003-11-01), Schreiner et al.
patent: 2004/0038305 (2004-02-01), Poston et al.
patent: 2004/0126828 (2004-07-01), Karumanchi et al.
patent: 2005/0025762 (2005-02-01), Karumanchi et al.
patent: 2005/0043227 (2005-02-01), Compernolle et al.
patent: 2005/0148040 (2005-07-01), Thadhani et al.
patent: 2005/0170444 (2005-08-01), Karumanchi et al.
patent: 2005/0256199 (2005-11-01), Durley et al.
patent: 2006/0067937 (2006-03-01), Karumanchi et al.
patent: 2006/0183175 (2006-08-01), Buhimschi et al.
patent: WO 98/28006 (1998-07-01), None
patent: WO 02/37120 (2002-05-01), None
patent: WO 2004/008946 (2004-01-01), None
patent: WO 2005/077007 (2005-08-01), None
patent: WO 2006/034507 (2006-03-01), None
patent: WO 2006/069373 (2006-06-01), None
patent: WO 2006/034507 (2007-04-01), None
patent: WO 2008/030283 (2008-03-01), None
The Merck Manual of Diagnosis and Therapy, 17thedition, 1999, Merck Research Laboratories, pp. 2057-2059.
Geissbuehler et al., Arch Gynecol Obstet, 2007, 276:151-157.
Irminger-Finger et al., International Journal of Biochemistry and Cell Biology, 2008, 40:1979-1983.
Bouloumie et al., “Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells,”Cardiovasc. Res. 41: 773-780 (1999).
Lenasi et al., “Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177and Thr495,”Cardiovasc. Res. 59: 844-853 (2003).
Ota et al., “Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells,”J. Cell. Physiol., 193: 299-318 (2002).
Tai et al., “Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel,”Arterioscler. Thromb. Vasc. Biol. 24: 405-412 (2004).
International Search Report dated Jan. 31, 2008 (PCT/US2007/12787).
Guerrero-Esteo et al., “Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II,”J. Biol. Chem. 277: 29197-29209 (2002).
Li et al., “Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer,”Int. J. Cancer(Pred. Oncol.) 89:122-126 (2000).
Miyazono, “Positive and negative regulation of TGF-β signaling,”J. Cell Science113: 1101-1109 (2000).
Miyazono et al., “Divergence and convergence of TGF-β/BMP signaling,”J. Cell. Physiol. 187: 265-276 (2001).
Nohe et al., “Signal transduction of bone morphogenetic protein receptors,”Cell. Signal. 16: 291-299 (2004).
Oswald et al., “Mesenchymal stem cells can be differentiated into endothelial cells in vitro,”Stem Cells22: 377-384 (2004).
Schultze-Mosgau et al., “Improved free vascular graft survival in an irradiated surgical site following topical application of rVEGF,”Int. J. Radiation Oncol. Biol. Phys. 57: 803-812 (2003).
Takahashi et al., “Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide,”Cancer Res. 61: 7846-7854 (2001).
Office Action for U.S. Appl. No. 11/235,577 mailed on Jul. 25, 2008.
Reply to Office Action for U.S. Appl. No. 11/235,577, filed on Nov. 25, 2008.
Office Action for U.S. Appl. No. 11/235,577 mailed on Feb. 18, 2009.
Reply to Office Action for U.S. Appl. No. 11/235,577, filed on May 18, 2009.
European Search Report issued on Jun. 11, 2008 for EP 05815390.9.
European Supplemental Search Report issued on Oct. 8, 2008 for EP 05815390.9.
European Examination Report issued on Mar. 20, 2009 for Application No. EP 05815390.9.
Singapore Written Opinion and Search Report issued on Oct. 30, 2008 for Application No. 200702085-2.
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen- A Review,”Placenta21:S16-S24 (2000).
Alberts et al., “Endoglin Gene Polymorphism as a Risk Factor for Sporadic Intracerebral Hemorrhage,”Ann. Neurol. 41:683-86 (1997).
Al Kadi et al., “A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birth weight,”Hum. Reprod. 20:3157-3162 (2005).
Barleon et al., “Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma From Healthy Donors,”Angiogenesis4:143-54 (2001).
Belgore et al., “Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Flt-1, in Fluid Samples: Development and Application of Two New Immunoassays,”Clin. Sci. 100:567-75 (2001).
Belgore et al., “Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor (SFIt-1) in Essential Hypertension,”Am. J. Cardiol. 87:805-7 (2001).
Belgore et al., “sFlt-1, a Potential Antagonist for Exogenous VEGF,”Circulation102:E108-E109 (2000).
Belgore et al., “Vascular Endothelial Growth Factor and its Receptor, Flt-1, in Smokers and Non-Smokers,”Br. J. Biomed. Sci. 57: 207-13 (2000).
Bellon et al., “Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions,”Eur. J. Immunol. 23:2340-2345 (1993).
Bernabeu et al., “Interaction between the CD45 antigen and phytohemagglutinin. Inhibitory effect on the lectin-induced T cell proliferation by anti-CD45 monoclonal antibody,”Eur. J. Immunol. 17:1461-1466 (1987).
Brennecke et al., “Reduction of placental nitric oxide synthase activity in pre-eclampsia,”Clin. Sci. 93:51-55 (1997).
Brockelsby et al., “VEGF Via VEGF Receptor-1 (Flt-1) Mimics Preeclamptic Plasma in Inhibiting Uterine Blood Vessel Relaxation in Pregnancy: Implications in the Pathogenesis of Preeclampsia,”Lab. Invest. 79:1101-11
Karumanchi S. Ananth
Letarte Michelle V.
Sukhatme Vikas P.
Toporsian Mourad
Beth Israel Deaconess Medical Center
Bieker-Brady Kristina
Clark & Elbing LLP
Harris Kimya F.
Szperka Michael
LandOfFree
Use of compounds that bind soluble endoglin and SFLT-1 for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of compounds that bind soluble endoglin and SFLT-1 for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compounds that bind soluble endoglin and SFLT-1 for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211655